Arg886
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Di-methylation Site Page: > Arg886  -  FAM120A (human)

Site Information
PPSQGrGrGFAGVCG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 9469312

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 )
Disease tissue studied:
colorectal cancer ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , colorectal carcinoma ( 2 , 3 , 4 , 5 , 6 , 7 , 8 )
Relevant cell line - cell type - tissue:
HCT116 (intestinal) ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , Jurkat (T lymphocyte) ( 1 , 11 ) , T lymphocyte ( 1 )

References 

1

Geoghegan V, et al. (2015) Comprehensive identification of arginine methylation in primary T cells reveals regulatory roles in cell signalling. Nat Commun 6, 6758
25849564   Curated Info

2

Possemato A (2010) CST Curation Set: 9392; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

3

Possemato A (2010) CST Curation Set: 8858; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

4

Possemato A (2010) CST Curation Set: 8852; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

5

Possemato A (2010) CST Curation Set: 8859; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

6

Possemato A (2010) CST Curation Set: 8854; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

7

Possemato A (2010) CST Curation Set: 8857; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

8

Possemato A (2010) CST Curation Set: 8853; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

9

Zhou J (2008) CST Curation Set: 5145; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

10

Zhou J (2008) CST Curation Set: 5146; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

11

Possemato A (2008) CST Curation Set: 3751; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info